UBS Group
MIRM icon

UBS Group’s Mirum Pharmaceuticals MIRM Stock Holding History

UBS Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.5M Sell
379,760
-115,234
-23% -$11.6M 0.01% 1862
2026
Q1 		$45.7M Buy
494,994
+174,211
+54% +$16.4M 0.01% 1732
2025
Q4 		$25.3M Buy
320,783
+44,941
+16% +$3.23M ﹤0.01% 2355
2025
Q3 		$20.2M Buy
275,842
+93,386
+51% +$5.94M ﹤0.01% 2548
2025
Q2 		$9.29M Sell
182,456
-53,501
-23% -$2.38M ﹤0.01% 3151
2025
Q1 		$10.6M Buy
235,957
+51,368
+28% +$2.42M ﹤0.01% 2973
2024
Q4 		$7.63M Buy
184,589
+60,199
+48% +$2.51M ﹤0.01% 3359
2024
Q3 		$4.85M Buy
124,390
+73,647
+145% +$2.94M ﹤0.01% 3104
2024
Q2 		$1.73M Sell
50,743
-106,168
-68% -$2.78M ﹤0.01% 3907
2024
Q1 		$3.94M Buy
156,911
+38,370
+32% +$1.05M ﹤0.01% 3223
2023
Q4 		$3.5M Buy
118,541
+118,348
+61,320% +$3.58M ﹤0.01% 3160
2023
Q3 		$6.1K Sell
193
-110,453
-100% -$3.02M ﹤0.01% 7319
2023
Q2 		$2.86M Buy
110,646
+70,080
+173% +$1.86M ﹤0.01% 3165
2023
Q1 		$974K Sell
40,566
-66,550
-62% -$1.52M ﹤0.01% 4121
2022
Q4 		$2.09M Buy
107,116
+89,139
+496% +$1.76M ﹤0.01% 3353
2022
Q3 		$378K Buy
+17,977
New +$433K ﹤0.01% 4579
2022
Q1 		– Sell
-2,481
Closed -$39K – 10644
2021
Q4 		$39K Buy
2,481
+1,727
+229% +$26.9K ﹤0.01% 7150
2021
Q3 		$15K Buy
+754
New +$12.3K ﹤0.01% 7503
2021
Q2 		– Sell
-1,161
Closed -$23K – 9633
2021
Q1 		$23K Sell
1,161
-13,393
-92% -$256K ﹤0.01% 7243
2020
Q4 		$254K Buy
14,554
+205
+1% +$4.03K ﹤0.01% 5091
2020
Q3 		$277K Sell
14,349
-1,448
-9% -$31.1K ﹤0.01% 4598
2020
Q2 		$307K Sell
15,797
-1,203
-7% -$20.1K ﹤0.01% 4498
2020
Q1 		$238K Buy
17,000
+12,183
+253% +$200K ﹤0.01% 4588
2019
Q4 		$118K Buy
4,817
+1,229
+34% +$13.1K ﹤0.01% 5919
2019
Q3 		$36K Buy
+3,588
New +$44K ﹤0.01% 6378

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's MIRM Position: Q2 2026 in Review

UBS Group reduced its Mirum Pharmaceuticals (MIRM) stake by 23% in Q2 2026, selling an estimated $11.6M and leaving 379,760 shares worth $44.5M. The position accounts for 0.01% of the portfolio, ranked #1862.

UBS Group first reported a position in MIRM in Q3 2019 and has held it in 25 quarters since. The position peaked at $45.7M in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • UBS Group held 379,760 shares of Mirum Pharmaceuticals worth $44.5M as of Q2 2026.
  • UBS Group sold 115,234 Mirum Pharmaceuticals shares in Q2 2026, an estimated $11.6M.
  • Mirum Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1862 holding.
  • UBS Group first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 25 quarters since.
  • UBS Group's Mirum Pharmaceuticals position peaked at $45.7M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.